Diabetes drug found no better than placebo at treating nonalcoholic fatty liver disease
A diabetes medication described in some studies as an effective treatment for nonalcoholic fatty liver disease (NAFLD) works no better than a placebo, report researchers after conducting the first randomized, double-blind, controlled clinical trial of sitagliptin, an oral antihyperglycemic marketed under the name Januvia.
Source: ScienceDaily Headlines - Category: Science Source Type: news
More News: Clinical Trials | Diabetes | Endocrinology | Fatty Liver Disease (FLD) | Januvia | Liver | Liver Disease | Non-alcoholic Fatty Liver Diseases (NAFLD) | Science | Study | Urology & Nephrology